针对性纳米基系统用于抗肥胖剂的输送
Ayse Basak Engin1, Evren Doruk Engin2, Atilla Engin3,4
1Faculty of Pharmacy, Department of Toxicology, Gazi University, Hipodrom, Ankara, Turkey. abengin@gmail.com.
Advances in experimental medicine and biology
|September 17, 2024
概括
纳米载体通过提高安全性和有效性来增强抗肥胖药物. 在纳米载体中将药物与微核糖核酸 (miRNAs) 结合起来,可以提供一种协同方法,以减少毒性来对抗肥胖.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 纳米技术 纳米技术
背景情况:
- 肥胖是一个慢性全球健康问题,与增加的死亡率和减少的预期寿命有关.
- 现有的抗肥胖药物往往因无效或不良副作用而受到影响.
- 纳米技术为克服肥胖治疗中的这些局限性提供了潜在的解决方案.
研究的目的:
- 审查纳米载体如何影响抗肥胖药物的特性和生物活性.
- 探索基于纳米载体的微核糖核酸 (miRNAs) 在肥胖治疗中的传递潜力.
- 评估使用纳米载体治疗肥胖症的联合药物和基因疗法的协同效应.
主要方法:
- 关于纳米载体在抗肥胖药物输送中的应用现有文献的综述.
- 分析纳米载体配方药物的药理动力学和生物分布特征.
- 通过纳米粒子传递的微核糖核酸 (miRNAs) 的作用的研究.
主要成果:
- 纳米载体可以通过减少系统毒性和增强向来提高抗肥胖药物的安全性.
- 封装的miRNAs在调节与肥胖相关的代谢途径和基因网络方面表现出有效性.
- 药物和基因在纳米载体中的联合递送表明,在较低剂量和毒性下,具有协同作用的抗肥胖作用.
结论:
- 纳米载体为开发更安全,更有效的抗肥胖疗法提供了一个有前途的平台.
- 使用纳米载体的向输送和组合疗法可以克服传统治疗的局限性.
- 对基于纳米载体的干预措施的进一步研究具有管理肥胖和相关并发症的巨大潜力.
关键词:
抗肥胖药物 抗肥胖药物 抗肥胖药物微核糖核酸 (miRNA) 是一种微核糖核酸.纳米载体的使用方法纳米颗粒 纳米颗粒纳米技术 纳米技术肥胖问题 肥胖问题复星醇是一种罗西格利塔 (Rosiglitazone) 是一种的药物.有针对性的交付目标.白色脂肪组织的脂肪组织.更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
10:16Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
7.5K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
